Myasthenia Gravis News

1 week ago | myastheniagravisnews.com | Lindsey Shapiro

The recently approved prefilled syringe formulation of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that offers the possibility of self-administration is now available in the U.S. for eligible adults with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChRs).

1 week ago | myastheniagravisnews.com | Margarida Maia

Plasma exchange — a procedure that clears antibodies, such as those that cause myasthenia gravis (MG), from the blood — may be a better myasthenic crisis treatment when used in combination with a procedure used to remove white blood cells, a study found. The combined procedure, called lymphoplasmapheresis, achieved better treatment outcomes than plasma exchange alone, in fewer treatment sessions. Both reduced the levels of MG-causing antibodies, but lymphoplasmapheresis appeared to perform better.

1 week ago | myastheniagravisnews.com | Marisa Wexler

Enrollment is now complete for a Phase 2 clinical trial testing Dianthus Therapeutics‘ treatment candidate DNTH103 in people with generalized myasthenia gravis (gMG). According to the developer, the initial results from the global study, dubbed MAGIC (NCT06282159), are expected by early fall. MAGIC was launched early last year and is being conducted at 56 locations in North and South America, Europe, and Asia.

2 weeks ago | myastheniagravisnews.com | Lindsey Shapiro

The U.S. Food and Drug Administration (FDA) has approved nipocalimab as a treatment for adults and adolescents, ages 12 and older, with generalized myasthenia gravis (gMG) who have antibodies against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) proteins. The newly approved therapy will be sold by developer Johnson & Johnson (J&J) under the brand name Imaavy. This is the first regulatory approval for Imaavy in gMG.

3 weeks ago | myastheniagravisnews.com | Andrea Lobo

People with generalized myasthenia gravis (gMG) who were misdiagnosed at least once and who have certain disease symptoms are more likely to see an increase in disease severity, according to a recent study. Ocular symptoms and/or muscle aches after physical activity were significantly associated with a higher risk of gMG worsening. Patients who are employed patients and those with fatigue were more likely to see their disease severity reduce or stabilize.